Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Shen, Lin; Kato, Ken; Kim, Sung‐Bae; A. Ajani, Jaffer; Zhao, Kuaile; He, Zhiyong; Yu, Xinmin; Shu, Yongqian; Luo, Qi; Wang, Jufeng; Chen, Zhendong; Niu, Zuoxing; Zhang, Longzhen; Yi, Tienan; Sun, Jong‐Mu; Chen, Jianhua; Yu, Guohua; Lin, Chen‐Yuan; Hara, Hiroki; Bi, Qing; Satoh, Taroh; Pazo-Cid, Roberto; Arkenau, Hendrick-Tobias; Borg, Christophe; Lordick, Florian; Li, Liyun; Ding, Ningning; Tao, Aiyang; Shi, Jingwen; Van Cutsem, Eric; the RATIONALE-302 Investigators, for

doi:10.1200/jco.21.01926

Public

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Published in Journal of Clinical Oncology • Apr 20, 2022

Authors:

Lin Shen

Ken Kato

Sung‐Bae Kim

Abstract

PURPOSE Patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) have poor prognosis. For these patients, treatment options are limited after first-line systemic therapy. PATIENTS AND METHODS In this open-label phase III clinical study, patients with advanced or metastatic ESCC...

Subject

Medicine

Docetaxel

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!